| 廖恒 余姝 黄智 何献策 罗薇.阿立哌唑与利培酮治疗难治性精神分裂症的临床疗效对比[J].现代生物医学进展英文版,2016,16(12):2333-2335. |
| 阿立哌唑与利培酮治疗难治性精神分裂症的临床疗效对比 |
| Comparison of Aripiprazole and Risperidone for Refractory Schizophrenia |
| |
| DOI： |
| 中文关键词: 阿立哌唑 利培酮 难治性精神分裂症 临床疗效 |
| 英文关键词: Aripiprazole Risperidone Refractory schizophrenia Clinical efficacy |
| 基金项目: |
|
| Hits: 809 |
| Download times: 0 |
| 中文摘要: |
| 目的：研究对比阿立哌唑与利培酮治疗难治性精神分裂症（简称难治性精分症）的临床疗效。方法：选择2012 年6 月至2015
年5 月在我院接受治疗的难治性精分症患者108 例进行研究。根据数字法随机将患者分成观察组及对照组各54 例，观察组给予
阿立哌唑治疗，对照组给予利培酮治疗，8 周后对比两组治疗后的总体疗效，不良反应情况，以及不同时期阴性与阳性症状量表
(PANSS)评分值。结果：观察组治疗后的总有效率92.59%，显著高于照组的77.78%（P＜0.05）。两组治疗1 周后～ 治疗8 周后的阳
性症状、阴性症状、一般病理及PANSS 总分均分别显著低于治疗前的水平（P＜0.05），且观察组治疗1 周后～治疗8 周后的阴性
症状及PANSS总分均分别显著低于对照组（P＜0.05）。观察组治疗后的不良反应总发生率为33.33%，显著低于对照组的64.81%
（P＜0.05）。结论：阿立哌唑较利培酮治疗难治性精分症可获得更好的疗效及安全性，建议可在临床进一步研究和推广应用。 |
| 英文摘要: |
| Objective:To study and compare the clinical efficacy of aripiprazole and risperidone in the treatment of refractory
schizophrenia.Methods:A total of 108 patients with refractory schizophrenia, who were treated in the Fourth People Hospital of
Chengdu fromJune 2012 to May 2015, were selected and randomly divided into observation group(n=54) and control group (n=54). The
observation group was treated with aripiprazole, while the control group ,with risperidone. The overall efficacy, adverse reactions, score
of positive and negative syndrome scale (PANSS) in different periods in the two groups were compared 8 weeks after treatment.Results:The total effective rate(92.59%) of observation group was significantly higher than that(77.78%) of control group(P<0.05). The positive
symptoms,negative symptoms, general pathology and PANSS total score in the two groups from 1 week to 8 weeks after treatment were
significantly lower than those before treatment (P<0.05), and the negative symptoms and PANSS total score in observation group were
significantly lower than those in control troup (P<0.05). The total incidence of adverse reactions (33.33%) in the observation group was
significantly lower than that (64.81%) in the control group (P<0.05).Conclusion:Aripiprazole can get better clinical efficacy and safety
than risperidone in the treatment of patients with refractory schizophrenia, which is worth to suggest for further research and application
in clinic. |
|
View Full Text
View/Add Comment Download reader |
| Close |
